Healthcare
I spent 3 days with pharma executives. They're suddenly taking longevity seriously.
I spent 3 days with pharma executives. They're suddenly taking longevity seriously.
Topic
Pharma-m-and-a
We are not tracking “pharma-m-and-a” as a topic yet, so here are the stories that mention it.
Healthcare
Abortion pill access jumps almost 50% after Australia eases restrictions for pharmacies
The number of pharmacies stocking the MS-2 Step medication increased from 2,228 to 4,107 after rules relaxed in 2023Get our breaking news email, free app or da…
Healthcare
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioriti…
Healthcare
Big Pharma's China deal spree grows with latest tie-up worth up to $7.8 billion
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
Healthcare
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?
JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.
Healthcare
Pharma stock soars 150% on injectables deal with Wegovy maker Novo
Shares in Swedish microcap stock Nanexa more than doubled after the drug-delivery group revealed a licensing deal with European pharma giant Novo Nordisk.
Healthcare
European drugmakers say they are 'losing ground' to US and Chinese rivals
Some of continent's biggest pharma firms write to national leaders calling for action to safeguard their futures. Some of Europe's biggest pharmaceutical compa…
Healthcare
Stocks making the biggest moves midday: Netflix, Xenon Pharmaceuticals, Coinbase, Sandisk, SpaceX & more
Here are some of the companies making headlines in midday trading.
Markets
Stocks making the biggest moves premarket: Netflix, Nucor, Xenon Pharmaceuticals & more
These are the stocks posting the largest moves premarket.
Healthcare
Mounjaro's maker has more room to run amid GLP-1 boom, Berenberg says
The firm upgraded the pharmaceutical stock to buy from hold.
Finance
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH
Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher…
Healthcare
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
Healthcare
Royalty Pharma to present at upcoming investor conferences
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conf…
Healthcare
Does iShares Pharma ETF Offer Superior Returns to Invesco's Equal Weight Healthcare Fund?
IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharp…
Healthcare
Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?
IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.
Healthcare
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Bought Rep. Gilbert Ray Cisneros, Jr.
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). In a filing disclosed…
Healthcare
Invesco Pharmaceuticals vs iShares Healthcare: Which Healthcare ETF Brings Better Profits
Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector ex…
Healthcare
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight
The chronic myeloid leukemia clinical trial analysis report delivers important insights into ongoing research of 25+ pipeline chronic myeloid leukemia drugs, c…
Geopolitics
'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat
Sandoz CEO Richard Saynor warns steep U.S. tariffs on imported generic drugs could force manufacturers to raise prices or cut supply.
Healthcare
STAT+: Pharmalittle: We're reading about another Novartis trial failure, a Novo Nordisk setback, and more
An experimental Novartis drug for a rare neuromuscular condition failed to improve muscle function in a pivotal study
